Recombinant mussel-like mucin (type III), nucleic acid molecule, fermentation strain, preparation method and application

By introducing biological functional peptides on type III mussel mucin and using dopa incorporation to express it, the biosafety reduction caused by tyrosinase residue was solved, and recombinant mussel mucin with high dopa content was prepared. , has excellent biological activity and meets industry standards.

CN118930659AActive Publication Date: 2024-11-12XIAMEN AISTRONDA MEDICAL TECHNOLOGY CO LTD

Patent Information

Application Number
CN202411123231.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-11-12
Estimated Expiration
2044-08-15

AI Technical Summary

Technical Problem

The residue of tyrosinase during the preparation of existing mussel mucins leads to a reduction in biosafety, which is difficult to meet the industry's requirements for dopa content.

Method used

Through genetic recombination technology, biological functional peptides were introduced on type III mussel mucin, and engineering strains such as E. coli were used for dopa incorporation and expression, and dopa modification was performed directly in the cells to avoid additional tyrosinase oxidation treatment. Recombinant mussel-like mucins with dopa content of 0.3 to 1.4 wt% were prepared.

Benefits of technology

Achieve high dopa content of recombinant mussel mucin, which has excellent biological activities, including cell migration, antioxidant, anti-inflammatory, tyrosinase inhibition and antibacterial effects, and solves the tyrosinase residues leading to The problem of low biosecurity and meets industry standards.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930659A_ABST
    Figure CN118930659A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biology, and discloses a recombinant mussel-like mucin (type III), a nucleic acid molecule, a fermentation strain, a preparation method and application. The recombinant mussel-like adhesive protein provided by the invention comprises a type III mussel adhesive protein and a biological functional peptide fragment (as shown in SEQ ID NO: 1, 5 and / or 8) which are connected through a peptide bond. According to the recombinant mussel-like mucin, biological functional peptide is introduced, and common engineering bacteria such as escherichia coli and the like can be directly subjected to dopa doping expression in cells by utilizing dopa, so that the recombinant mussel-like mucin with high dopa content is obtained; the problem that the biological safety is reduced due to the introduction of tyrosinase in the existing mussel mucoprotein preparation can be effectively solved; meanwhile, the recombinant mussel mucoprotein has good biological activities of promoting cell migration, scavenging free radicals, resisting inflammation, inhibiting bacteria, inhibiting tyrosinase, soothing skin and the like, has huge potential of serving as a skin repair active component, and can be well applied to the field of medical treatment and / or cosmetics.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and in particular relates to a recombinant mussel-like mucin (type III), a nucleic acid molecule, an engineering strain, and a preparation method and application thereof. Background Art

[0002] Mussel adhesive protein (MAP), also known as mussel byssin, is a special type of adhesive protein synthesized by the foot glands of marine shellfish such as blue mussel, thick-shelled mussel, and green mussel and secreted into the byssin; it has the functions of promoting cell adhesion and crawling, promoting wound healing, inhibiting itching, broad-spectrum adhesion, and forming a water-resistant protective film. Mussel adhesive protein has broad application prospects and industrial development prospects in the fields of medicine, food, environmental protection, and materials science.

[0003] Mussel mucin has a strong function of adhering to the matrix, which is related to its special molecular structure, DOPA-mediated interchain crosslinking and the interaction mode with the substrate. In addition, it has good biocompatibility and degradability, and is a kind of biological adhesive with great advantages and potential. Mussel mucin crosslinks with each other through electrostatic interaction, hydrophobic interaction and oxidized DOPA groups and unoxidized DOPA groups to form a microscopic biological scaffold, which strongly adheres to the wound surface and plays a role in promoting healing and relieving itching and pain by water isolation. That is, the content of DOPA in mussel mucin will affect its biological activity. Therefore, in the preparation process of mussel mucin, tyrosinase is introduced to oxidatively modify it and increase the DOPA content to obtain a mussel mucin with excellent biological activity.

[0004] However, there may be a problem of tyrosinase residues in this process, which leads to reduced biosafety of the prepared mussel mucin and has great limitations. Summary of the invention

[0005] The first object of the present invention is to provide a recombinant mussel-like mucin. The recombinant mussel-like mucin has biological activity comparable to or even better than that of existing mussel mucins, and can be directly expressed by DOPA incorporation in cells of common engineering bacteria such as Escherichia coli, so that the recombinant mussel-like mucin is modified by DOPA and does not need to be subjected to additional tyrosinase oxidation treatment, thus meeting the requirements of the industry standard for the DOPA content of mussel mucins, and effectively solving the problem of reduced biosafety caused by the introduction of tyrosinase in the preparation of existing mussel mucins.

[0006] The second object of the present invention is to provide a nucleic acid molecule.

[0007] The third object of the present invention is to provide a fermentation strain.

[0008] The fourth object of the present invention is to provide a method for preparing the above-mentioned recombinant mussel-like mucin.

[0009] The fifth object of the present invention is to provide the use of the above-mentioned recombinant mussel-like mucin, nucleic acid molecule and / or fermentation strain in the field of medicine and / or cosmetics.

[0010] Specifically, the recombinant mussel mucin provided by the present invention includes type III mussel mucin and a biological functional peptide segment, and the type III mussel mucin and the biological functional peptide segment are connected by a peptide bond; the biological functional peptide segment includes one or more of fragment I, fragment II and fragment III, the amino acid sequence of fragment I is shown in SEQ ID NO:2, the amino acid sequence of fragment II is shown in SEQ ID NO:5, and the amino acid sequence of fragment III is shown in SEQ ID NO:8.

[0011] Furthermore, the amino acid sequence of the type III mussel mucin is shown in SEQ ID NO:1.

[0012] Furthermore, the amino acid sequence of the recombinant mussel-like mucin is shown in SEQ ID NO:3.

[0013] Furthermore, the amino acid sequence of the recombinant mussel-like mucin is shown in SEQ ID NO:6.

[0014] Furthermore, the amino acid sequence of the recombinant mussel-like mucin is shown in SEQ ID NO:9.

[0015] Furthermore, the DOPA content of the recombinant mussel-like mucin is 0.3-1.4 wt%.

[0016] The nucleic acid molecule provided by the invention encodes the above-mentioned recombinant mussel-like mucin.

[0017] Furthermore, the nucleic acid molecule includes one or more of the nucleotide fragments shown in SEQ ID NOs: 4, 7 and 10.

[0018] The fermentation strain provided by the invention synthesizes and expresses the above-mentioned recombinant mussel-like mucin.

[0019] The preparation method of the recombinant mussel-like mucin provided by the present invention comprises: S1, introducing the above-mentioned nucleic acid molecule into a host cell to obtain a fermentation strain; S2, taking the fermentation strain for fermentation culture and inducing expression to obtain the recombinant mussel-like mucin; wherein DOPA and an inducing expression agent are added in the inducing expression.

[0020] Furthermore, in step S2, the culture medium for the fermentation culture is selected from one or more of LB culture medium, EMB culture medium, MAC culture medium and MS culture medium.

[0021] Furthermore, in step S2, the cell inoculation amount of the fermentation culture is 0.5×10 5 ~1.5×10 5 / mL, temperature is 25-37℃, and time is 4-8h.

[0022] Furthermore, in step S2, during the induced expression, the concentration of DOPA is 0.1-1.0 g / L, and the concentration of the inducing expression agent is 0.1-1 mM.

[0023] Furthermore, the induction expression temperature is 16-37°C and the time is 4-10 hours.

[0024] The present invention also provides the use of the recombinant mussel-like mucin, nucleic acid molecule and / or fermentation strain in the field of medicine and / or cosmetics.

[0025] Beneficial effects:

[0026] The invention provides a recombinant mussel-like mucin, which specifically comprises a type III mussel mucin and a biological functional peptide segment connected by a peptide bond, and can promote the incorporation and expression of DOPA in cells of common engineering bacteria such as Escherichia coli, so that DOPA can be directly utilized in the cells to obtain a recombinant mussel-like mucin with a high DOPA content. The DOPA content in the recombinant mussel-like mucin reaches 0.3-1.4wt%, which meets the requirements of the industry standard for the DOPA content, and can effectively solve the problem of reduced biosafety caused by the introduction of tyrosinase in the existing mussel mucin preparation. The recombinant mussel-like mucin has a biological activity equivalent to or better than that of the existing mussel mucin, and has a good application prospect. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 The gel electrophoresis diagram of the recombinant mussel-like mucin provided in Examples 1 to 3 and Comparative Examples 1 to 4 of the present invention;

[0028] Figure 2 This is a graph showing the experimental results of the test on the cell migration promoting effect of the recombinant mussel-like mucin provided in Example 4 of the present invention (scale is 100 μm);

[0029] Figure 3 This is a graph showing the experimental results of the antibacterial effect test of the recombinant mussel-like mucin provided in Example 4 of the present invention;

[0030] Figure 4 This is a graph showing the experimental results of the skin soothing effect test of the recombinant mussel-like mucin provided in Example 4 of the present invention. DETAILED DESCRIPTION

[0031] The amino acid and nucleotide sequences involved in this application are specifically shown in Table 1.

[0032] Table 1.

[0033]

[0034]

[0035]

[0036] The inventors of the present invention have found through extensive and in-depth research that by introducing a biological functional peptide derived from a specific domain of fibronectin into type III mussel mucin, common engineering bacteria such as Escherichia coli can be used to synthesize protein with DOPA incorporation, thereby obtaining a recombinant mussel mucin with a high DOPA content. Therefore, the recombinant mussel mucin does not need to introduce tyrosinase for tyrosine modification in vitro, which can well meet the industry's requirements for DOPA content and effectively solve the problem of reduced biosafety caused by tyrosinase residues in the prior art. Based on this, the technical solution of the present invention is obtained.

[0037] In the present invention, the recombinant mussel mucin refers to a polypeptide similar to mussel mucin obtained by genetically manipulating and / or modifying the gene encoding the desired mussel mucin using gene recombination technology, thereby introducing a biological functional peptide segment into the type III mussel mucin; and using a plasmid or viral vector to introduce the target into a suitable host cell for expression, and then preparing it through purification treatment and other operations.

[0038] In the present invention, the recombinant mussel mucin specifically includes type III mussel mucin and biological functional peptide segments, and the type III mussel mucin and the biological functional peptide segments are connected by peptide bonds.

[0039] In the present invention, the type III mussel mucin is the type with the smallest molecular weight among the six types of mussel mucin, and its specific amino acid sequence is specifically shown in SEQ ID NO:1.

[0040] In the present invention, the biological functional peptide segment includes one or more of fragment I, fragment II and fragment III. Among them, the fragment I is derived from the FN-C / H-II functional peptide segment of fibronectin, and its specific amino acid sequence is shown in SEQ ID NO: 2. The fragment II is derived from the Type IIICS-1 functional peptide segment of fibronectin, and its specific amino acid sequence is shown in SEQ ID NO: 5. The fragment III is derived from the Type IIICS-5 functional peptide segment of fibronectin, and its specific amino acid sequence is shown in SEQ ID NO: 8.

[0041] It should be noted that the "I", "II" and "III" in the above-mentioned fragments I, II and III are only used to distinguish different biological functional peptides for the convenience of description and have no other meanings and do not affect the scope of protection of the present invention.

[0042] In the present invention, the biological functional peptide is specifically connected to the N-terminus and / or C-terminus of the type III mussel mucin. In some embodiments, the biological functional peptide is preferably connected to the C-terminus of the type III mussel mucin. At this time, the recombinant mussel mucin has high DOPA content and also has excellent biological activities such as promoting cell migration, anti-oxidation, anti-inflammatory, tyrosinase inhibition and antibacterial.

[0043] In some specific embodiments, the amino acid sequence of the recombinant mussel-like mucin is preferably as shown in SEQ ID NO: 3. At this time, the recombinant mussel-like mucin has high DOPA content and also has excellent biological activities such as promoting cell migration, anti-oxidation, anti-inflammatory, tyrosinase inhibition and antibacterial.

[0044] In some specific embodiments, the amino acid sequence of the recombinant mussel-like mucin is preferably as shown in SEQ ID NO: 6. At this time, the recombinant mussel-like mucin has high DOPA content and also has excellent biological activities such as promoting cell migration, anti-oxidation, anti-inflammatory, tyrosinase inhibition and antibacterial.

[0045] In some specific embodiments, the amino acid sequence of the recombinant mussel-like mucin is preferably as shown in SEQ ID NO:9.

[0046] In the present invention, the DOPA content of the recombinant mussel-like mucin is preferably 0.3-1.4wt%, such as 0.3wt%, 0.5wt%, 0.7wt%, 0.85wt%, 0.88wt%, 0.9wt%, 1.0wt%, 1.1wt%, 1.18wt%, 1.25wt%, 1.37wt%, 1.4wt% or any value therebetween. At this time, the recombinant mussel-like mucin has a high DOPA content without the need for in vitro modification by tyrosinase, and satisfies the requirements of the industry standard for the DOPA content of the recombinant mussel-like mucin, without the problem of low biosafety caused by tyrosinase residues.

[0047] Based on the purpose of preparing the above recombinant mussel-like mucin, the present invention also provides a nucleic acid molecule, which includes a nucleotide fragment encoding the above recombinant mussel-like mucin.

[0048] In the present invention, the nucleic acid molecule preferably includes one or more of the nucleotide fragments shown in SEQ ID NO: 4, 7 and 10. At this time, the nucleic acid molecule is a sequence optimized for E. coli codons, which can better synthesize and express the above-mentioned recombinant mussel-like mucin in E. coli cells.

[0049] In the present invention, the nucleic acid molecule is preferably constructed by introducing one or more of the nucleotide fragments shown in SEQ ID NOs: 4, 7 and 10 into a plasmid vector. In some specific embodiments, specific examples of the plasmid vector include but are not limited to: one or more of pET-28a, pET-30a, pET-32a and pGEX4T-1.

[0050] Based on the purpose of preparing the above-mentioned recombinant mussel-like mucin, the present invention also provides a fermentation strain that can efficiently synthesize and express the above-mentioned recombinant mussel-like mucin.

[0051] In the present invention, the fermentation strain includes the above-mentioned nucleic acid molecule encoding the recombinant mussel-like mucin and the corresponding protein expression system, so that it can be transcribed under the guidance of the above-mentioned nucleic acid molecule, and translated using amino acids and exogenous DOPA based on the guidance of the transcription product, thereby obtaining a recombinant mussel-like mucin with excellent biological activity and a high DOPA content.

[0052] In the present invention, the fermentation strain is a type of receptor cell conventionally used in existing genetic engineering technology. Those skilled in the art can make adaptive selections according to actual needs, and the present invention does not specifically limit its specific type, source and culture conditions. In some specific embodiments, specific examples of the fermentation strain include but are not limited to: one or more of Escherichia coli BL21, Escherichia coli BL21 (DE3) and Escherichia coli BL21 Star (DE3).

[0053] Based on the purpose of preparing the above-mentioned recombinant mussel-like mucin, the present invention also provides a method for preparing the recombinant mussel-like mucin. The preparation method specifically comprises: S1, introducing the above-mentioned nucleic acid molecule into a host cell to obtain a fermentation strain; S2, fermenting and induced expression of the fermentation strain to obtain the recombinant mussel-like mucin; wherein DOPA and an inducing expression agent are added during the induced expression.

[0054] In the present invention, the introduction of the nucleic acid molecule into the host cell in step S1 is a conventional technique used in the field of genetic engineering. Those skilled in the art can make adaptive selections according to actual needs, and the present invention does not impose any particular restrictions on the specific steps, reagents and conditions. In some specific embodiments, specific examples of the method for introducing the nucleic acid molecule into the host cell include but are not limited to: one or more of calcium phosphate precipitation method, microinjection method, virus infection method, liposome-mediated infection method and electric shock method.

[0055] In the present invention, the host cell is a type of receptor cell conventionally used in existing genetic engineering technology. Those skilled in the art can make adaptive selections according to actual needs, and the present invention does not impose any particular restrictions on its specific type, source, and culture conditions. In some specific embodiments, specific examples of the host cell include but are not limited to: one or more of Escherichia coli BL21, Escherichia coli BL21 (DE3), and Escherichia coli BL21 Star (DE3).

[0056] In the present invention, in the fermentation culture of step S2, those skilled in the art may adaptively adjust the culture medium and culture conditions used according to the host cells used. This is a conventional technical means in the prior art and the present invention does not impose any particular limitation on it.

[0057] In some specific embodiments, specific examples of the culture medium used in the fermentation culture include but are not limited to: one or more of LB medium, EMB medium, MAC medium and MS medium.

[0058] In some specific embodiments, the fermentation culture conditions include a cell inoculum size of preferably 0.5×10 5 ~1.5×10 5 Pieces / mL, such as 0.5×10 5 / mL, 0.8×10 5 / mL, 1×10 5 / mL, 1.5×10 5 / mL or any value therebetween; the temperature is preferably 25-37°C, such as 25°C, 26°C, 28°C, 30°C, 31°C, 35°C, 37°C or any value therebetween; the time is preferably 4-8h, such as 4h, 4.5h, 5h, 6h, 7h, 8h or any value therebetween. At this time, the above fermentation culture conditions are conducive to the synthesis and expression of proteins in the host cells, thereby obtaining a recombinant mussel-like mucin with a higher DOPA content.

[0059] In the present invention, the induced expression in step S2 specifically includes: adding DOPA and an inducing expression agent to the fermented culture solution to induce the host cell to express the recombinant mussel-like mucin. The expression of the recombinant mussel-like mucin includes normal protein expression using amino acids and DOPA incorporation expression using DOPA instead of tyrosine to introduce a certain amount of DOPA into the recombinant mussel-like mucin.

[0060] In some specific embodiments, in the induced expression of step S2, the concentration of DOPA is preferably 0.1-1.0 g / L, such as 0.1 g / L, 0.18 g / L, 0.2 g / L, 0.3 g / L, 0.4 g / L, 0.8 g / L, 1 g / L or any value therebetween. At this time, the use of the above DOPA concentration is conducive to the host cell uptake and utilization of DOPA, thereby better achieving DOPA incorporation expression, thereby obtaining a recombinant mussel-like mucin with a higher DOPA content.

[0061] In the present invention, in the induced expression of step S2, the inducing agent is a type of substance conventionally used in genetic engineering technology to induce host cells to efficiently express proteins. Those skilled in the art can make adaptive choices according to actual needs, and the present invention does not impose any particular limitation on it. In some specific embodiments, specific examples of the inducing agent include but are not limited to: one or more of isopropylthiogalactoside, lactose and arabinose.

[0062] In some specific embodiments, in the induced expression of step S2, the concentration of the induced expression agent is preferably 0.1-1 mM, such as 0.1 mM, 0.15 mM, 0.2 mM, 0.3 mM, 0.4 mM, 0.5 mM, 0.8 mM, 1 mM or any value therebetween. At this time, the above-mentioned induced expression agent concentration can well induce the host cell to express the recombinant mussel-like mucin, thereby effectively increasing the yield of the recombinant mussel-like mucin.

[0063] In some specific embodiments, the induction expression conditions include a temperature of preferably 16 to 37°C, such as 16°C, 18°C, 20°C, 25°C, 30°C, 35°C or any value therebetween; and a time of preferably 4 to 10 hours, such as 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 10 hours or any value therebetween. At this time, the above-mentioned induction expression conditions are conducive to the incorporation and expression of DOPA in the host cell, thereby effectively increasing the amount of DOPA incorporation, so as to finally obtain a recombinant mussel-like mucin with a higher DOPA content.

[0064] The recombinant mussel-like mucin provided by the present invention has good biological activities of promoting cell migration, scavenging free radicals, anti-inflammatory, antibacterial, tyrosinase inhibition and skin soothing, and can therefore be used as an active ingredient for promoting skin repair.

[0065] The invention also provides the use of the above-mentioned recombinant mussel-like mucin, nucleic acid molecule and / or fermentation strain in the field of medicine and / or cosmetics.

[0066] Embodiments of the present invention are described in detail below, and the examples of the embodiments are intended to be used to explain the present invention, but should not be construed as limiting the present invention. In the embodiments, if specific techniques or conditions are not specified, the techniques or conditions described in the literature in this area or the product specifications are used. If the manufacturer is not specified for reagents or instruments used, they are all conventional products that can be obtained commercially.

[0067] Example 1

[0068] This example is used to illustrate a recombinant mussel-like mucin and its preparation, wherein the recombinant mussel-like mucin comprises type III mussel mucin (amino acid sequence as shown in SEQ ID NO: 1) and fibronectin FN-C / H-II (amino acid sequence as shown in SEQ ID NO: 2) connected by peptide bonds. The preparation of the recombinant mussel-like mucin specifically comprises:

[0069] 1. Construction of fermentation strain:

[0070] (1) According to the amino acid sequence of the recombinant mussel-like mucin (as shown in SEQ ID NO: 3), after codon optimization of the Escherichia coli expression system, a DNA fragment (nucleotide sequence as shown in SEQ ID NO: 4) capable of efficiently expressing the recombinant mussel-like mucin in Escherichia coli was synthesized.

[0071] (2) After adding NdeⅠ and XhoⅠ restriction sites at both ends of the DNA fragment, it was synthesized and digested with NdeⅠ and XhoⅠ before being recombined into the pET-30a vector to obtain a recombinant plasmid.

[0072] (3) The recombinant plasmid was transformed into competent Escherichia coli BL21 (DE3) cells and spread onto a solid LB plate (including 10 g / L tryptone, 5 g / L yeast extract, 10 g / L sodium chloride and 15 g / L agar) containing 100 mg / mL ampicillin, and cultured overnight at 37°C to obtain single colonies; a portion of cells from each single colony was taken for PCR identification and sequencing to obtain a positive single colony, which was the fermentation strain.

[0073] 2. Fermentation culture and induced expression of fermentation strains:

[0074] (1) According to 1×10 5A single positive colony was picked with an inoculum size of 100 / mL and inoculated into LB liquid culture medium (including 10 g / L tryptone, 5 g / L yeast extract and 10 g / L sodium chloride) containing 100 mg / mL ampicillin, and fermented in a shaking incubator at 37°C and 250 r / min for 8 h to obtain a fermentation culture solution.

[0075] (2) IPTG and DOPA were added to the seed solution at final concentrations of 0.1 mM and 1 g / L, and the expression was induced in a shaking incubator at 28°C and 250 r / min for 10 h to obtain an induced expression bacterial solution.

[0076] 3. Purification of recombinant mussel-like mucin:

[0077] (1) Take 50 mL of the induced expression bacterial solution and centrifuge it at 4°C and 10,000 r / min for 15 min, and remove the supernatant; take 10 mL of lysis buffer (4°C, including 10 mM PBS buffer (pH = 7.4), 10 mM EDTA and 1% TritonX-100) and add it to the precipitate for resuspending to obtain a resuspended bacterial solution.

[0078] (2) The resuspended bacterial solution was broken by a high-pressure homogenizer in an ice bath until the bacterial solution was clear (pressure was 600-900 bar). The solution was then centrifuged at 4°C and 9000 r / min for 20 min, and the supernatant was removed to obtain protein inclusion bodies.

[0079] (3) taking a dissolving solution (including 10 mM HAc and 8 mM urea) to dissolve the protein inclusion bodies to obtain a protein dissolving solution; taking 600 μL of the protein dissolving solution each time and adding it to the G-25 desalting column until all the mixed solution is added, then taking 10 mM PBS buffer (pH = 7.4) for elution, collecting the eluate, and obtaining a purified recombinant mussel mucin solution.

[0080] Figure 1 This is the experimental result of gel electrophoresis of purified recombinant mussel-like mucin solution. Figure 1 It can be seen that the recombinant mussel-like mucin provided in this example has a certain viscosity, a slow electrophoresis speed, a molecular weight of about 9.72 kD, and the obtained recombinant mussel-like mucin has a high purity.

[0081] Example 2

[0082] The present embodiment provides a recombinant mussel-like mucin and its preparation, wherein the recombinant mussel-like mucin comprises type III mussel mucin (amino acid sequence as shown in SEQ ID NO: 1) and Type IIICS-1 of fibronectin (amino acid sequence as shown in SEQ ID NO: 5) connected by peptide bonds.

[0083] The amino acid sequence of the recombinant mussel-like mucin is shown in SEQ ID NO:6, and its preparation is basically the same as the preparation method provided in Example 1, except that the nucleotide of the DNA fragment used in the construction of the fermentation strain in "Step 1" is shown in SEQ ID NO:7, and other conditions are the same to obtain the recombinant mussel-like mucin.

[0084] Figure 1 This is the experimental result of gel electrophoresis of purified recombinant mussel-like mucin solution. Figure 1 It can be seen that the recombinant mussel-like mucin provided in this embodiment has a certain viscosity, a slow electrophoresis speed, a molecular weight of about 8.85 kD, and the obtained recombinant mussel-like mucin has a high purity.

[0085] Example 3

[0086] This embodiment provides a recombinant mussel-like mucin and its preparation, wherein the recombinant mussel-like mucin comprises type III mussel mucin (amino acid sequence as shown in SEQ ID NO: 1) and Type IIICS-5 of fibronectin (amino acid sequence as shown in SEQ ID NO: 8) connected by peptide bonds.

[0087] The amino acid sequence of the recombinant mussel-like mucin is shown in SEQ ID NO:9, and its preparation is basically the same as the preparation method provided in Example 1, except that the nucleotide of the DNA fragment used in the construction of the fermentation strain in "Step 1" is shown in SEQ ID NO:10, and other conditions are the same to obtain the recombinant mussel-like mucin.

[0088] Figure 1 This is the experimental result of gel electrophoresis of purified recombinant mussel-like mucin solution. Figure 1 It can be seen that the recombinant mussel-like mucin provided in this embodiment has a certain viscosity, a slow electrophoresis speed, a molecular weight of about 8.50 kD, and the obtained recombinant mussel-like mucin has a high purity.

[0089] Comparative Example 1

[0090] The comparative example provides a recombinant mussel-like mucin and its preparation, wherein the recombinant mussel-like mucin comprises type III mussel mucin (amino acid sequence as shown in SEQ ID NO: 1) and Type III-10 of fibronectin (amino acid sequence as shown in SEQ ID NO: 11) connected by peptide bonds.

[0091] The amino acid sequence of the recombinant mussel-like mucin is shown in SEQ ID NO: 12, and its preparation is basically the same as the preparation method provided in Example 1, except that the nucleotide of the DNA fragment used in the construction of the fermentation strain in "step 1" is shown in SEQ ID NO: 13, and other conditions are the same to obtain the recombinant mussel-like mucin.

[0092] Figure 1 This is the experimental result of gel electrophoresis of purified recombinant mussel-like mucin solution. Figure 1 It can be seen that the molecular weight of the recombinant mussel-like mucin provided in this comparative example is about 8.33 kD.

[0093] Comparative Example 2

[0094] This comparative example provides a recombinant mussel-like mucin and its preparation, wherein the recombinant mussel-like mucin comprises type III mussel mucin (amino acid sequence as shown in SEQ ID NO: 1) and fibronectin FN-C / H-IV (amino acid sequence as shown in SEQ ID NO: 14) connected by peptide bonds.

[0095] The amino acid sequence of the recombinant mussel-like mucin is shown in SEQ ID NO: 15, and its preparation is basically the same as the preparation method provided in Example 1, except that the nucleotide of the DNA fragment used in the construction of the fermentation strain in "step 1" is shown in SEQ ID NO: 16, and other conditions are the same to obtain the recombinant mussel-like mucin.

[0096] Figure 1 This is the experimental result of gel electrophoresis of purified recombinant mussel-like mucin solution. Figure 1 It can be seen that the molecular weight of the recombinant mussel-like mucin provided in this comparative example is about 9.02 kD.

[0097] Comparative Example 3

[0098] This comparative example provides a recombinant mussel-like mucin and its preparation, wherein the recombinant mussel-like mucin comprises type III mussel mucin (amino acid sequence as shown in SEQ ID NO: 1) and fibronectin FN-C / HV) (amino acid sequence as shown in SEQ ID NO: 17) connected by peptide bonds.

[0099] The amino acid sequence of the recombinant mussel-like mucin is shown in SEQ ID NO: 18, and its preparation is basically the same as the preparation method provided in Example 1, except that the nucleotide of the DNA fragment used in the construction of the fermentation strain in "step 1" is shown in SEQ ID NO: 19, and other conditions are the same to obtain the recombinant mussel-like mucin.

[0100] Figure 1This is the experimental result of gel electrophoresis of purified recombinant mussel-like mucin solution. Figure 1 It can be seen that the molecular weight of the recombinant mussel-like mucin provided in this comparative example is about 9.01 kD.

[0101] Comparative Example 4

[0102] This comparative example provides a recombinant mussel-like mucin and its preparation. The amino acid sequence of the recombinant mussel-like mucin is shown in SEQ ID NO: 1, and its preparation is basically the same as the preparation method provided in Example 1, except that the nucleotide of the DNA fragment used in the construction of the fermentation strain in "step 1" is shown in SEQ ID NO: 20, and other conditions are the same to obtain the recombinant mussel-like mucin.

[0103] Figure 1 This is the experimental result of gel electrophoresis of purified recombinant mussel-like mucin solution. Figure 1 It can be seen that the molecular weight of the recombinant mussel-like mucin provided in this comparative example is about 8.00 kD.

[0104] Example 4

[0105] In this example, the DOPA content of the recombinant mussel mucin provided in the above examples and comparative examples was determined by referring to the method specified in Appendix B of YY / T 1293.6-2020. The specific results are shown in Table 2.

[0106] Table 2.

[0107]

[0108]

[0109] It can be seen from the test results described in Table 2 that compared with the recombinant mussel mucin provided in Comparative Example 4, the DOPA content in the recombinant mussel mucin provided in Examples 1 to 3 of the present invention is as high as 1.18 to 1.27 wt %, and the DOPA content is increased by 2.11 to 2.45 times.

[0110] Example 5

[0111] This example is used to illustrate the biological activity of the recombinant mussel-like mucin provided in the above examples and comparative examples. The recombinant mussel-like mucin was mixed with PBS buffer (pH=7.4) to prepare a 0.5 μg / mL protein solution, and the protein solution was used to perform the following tests:

[0112] 1. Promoting cell migration: According to 1×10 5Hacat cells were inoculated with a volume of 100 μL / mL in DMEM medium (Merck, catalog number D6429) containing 10% FBS to obtain cell fluid; 100 μL was added to the cell well, and the plug was inserted, and incubated at 37°C for 24 hours to form scratches; the plug was removed, and the protein solution was added to the well at a final concentration of 0.2 mg / mL, and an equal volume of DMEM medium containing 10% FBS and PBS buffer (pH = 7.4) were used as blank control and negative control, respectively, and incubated at 37°C for 24 hours; the incubated cell plate was washed 3 times with PBS buffer (pH = 7.4), and the cell adhesion was observed under a microscope. The results are as follows Figure 2 shown.

[0113] Depend on Figure 2 It can be seen from the test results shown that, compared with the negative control, the recombinant mussel-like mucin provided by Examples 1 to 3 of the present invention has an obvious effect of promoting cell migration and can be used as an active ingredient for promoting skin repair.

[0114] 2. In vitro free radical scavenging effect: The protein solution was mixed with 0.1 mM DPPH solution at a final concentration of 0.8 mg / mL, and the DPPH free radical scavenging rate of the recombinant mussel-like mucin was determined according to the method of "Cosmetics-Free Radical (DPPH) Scavenging Experimental Method". The results are shown in Table 3.

[0115] Table 3.

[0116] Group DPPH free radical scavenging rate (%) Example 1 72.6 Example 2 79.5 Example 3 78.9 Comparative Example 1 72.2 Comparative Example 2 66.3 Comparative Example 3 56.9 Comparative Example 4 73.4

[0117] From the test results shown in Table 3, it can be seen that the recombinant mussel-like mucin provided by Examples 1 to 3 of the present invention has an excellent DPPH free radical scavenging rate and can be used as an antioxidant active ingredient.

[0118] 3. Anti-inflammatory effect: RAW264.7 macrophages were used as a cell model and treated according to the following groups:

[0119] (1) Blank control group: 1×10 5 RAW264.7 macrophages were inoculated with a seeding volume of 100 / mL into DMEM medium containing 10% FBS and cultured in an incubator at 37°C and 5% CO2 for 24 h;

[0120] (2) Inflammation model group: In addition to the blank control group, LPS with a final concentration of 1 μg / mL was added to the DMEM medium to induce inflammation;

[0121] (3) Experimental group: Based on the treatment of the inflammation model group, the recombinant mussel-like mucin provided in the above examples was added to the DMEM medium at a final concentration of 60 μg / mL;

[0122] (4) Comparative experimental group: Based on the treatment of the inflammatory model group, the recombinant mussel mucin provided in the above comparative example was added to the DMEM medium at a final concentration of 60 μg / mL;

[0123] (5) Positive control group: In addition to the treatment of the inflammatory model group, dexamethasone with a final concentration of 0.1 mg / mL was added to the DMEM culture medium.

[0124] After the culture was completed, the cell culture fluid of each group was centrifuged, the supernatant was collected, and the NO content of the supernatant was detected using a nitric oxide (NO) assay kit (Shanghai Xuanya Biology, catalog number 012-1) according to the instructions. The test results are shown in Table 4.

[0125] Table 4.

[0126]

[0127] From the test results shown in Table 4, it can be seen that the NO content in the cell culture fluid of the inflammatory model group is significantly increased compared with the blank control group, indicating that the inflammatory cell model was successfully constructed. Compared with Comparative Examples 1 to 3, the co-treatment of RAW264.7 macrophages with the recombinant mussel-like mucin provided by Examples 1 to 3 of the present invention and LNP can significantly alleviate the cell inflammation caused by the action of LNP, has excellent anti-inflammatory effects, and can be used as an active ingredient for repairing inflamed skin.

[0128] 4. Antibacterial effect: add protein solution with a final concentration of 0.5 mg / mL and a cell concentration of 1×10 5 The culture medium was mixed with 100 μL of Propionibacterium acnes liquid, and DPBS solution was used as a blank control, and tetracycline with a final concentration of 0.1 mg / mL was used as a positive control. Finally, DPBS solution was used to make up to 200 μL to obtain a mixed culture medium; 150 μL of the mixed culture medium was spread on a plate, cultured in an anaerobic incubator at 35°C for 48 hours, and the cell adhesion was observed under a microscope. The results are as follows Figure 3 shown.

[0129] Depend on Figure 3 The test results shown show that the recombinant mussel-like mucin provided in Examples 1 to 3 of the present invention has an excellent antibacterial effect on Propionibacterium acnes and can be used as an acne-removing and antibacterial active ingredient.

[0130] 5. Tyrosinase inhibition: The protein solution was mixed with 0.1 mM tyrosine solution at a final concentration of 0.8 mg / mL, and the tyrosinase inhibition rate of the recombinant mussel-like mucin was determined according to the method of "Cosmetics-Tyrosinase Activity Inhibition Test Method". The results are shown in Table 5.

[0131] Table 5.

[0132] Group Tyrosinase inhibition rate (%) Example 1 81.1 Example 2 84.0 Example 3 85.5 Comparative Example 1 41.9 Comparative Example 2 50.4 Comparative Example 3 70.8 Comparative Example 4 45.8

[0133] From the test results shown in Table 5, it can be seen that the recombinant mussel-like mucin provided by Examples 1 to 3 of the present invention has an excellent inhibitory effect on tyrosinase and can be used as a whitening active ingredient.

[0134] 6. Skin soothing effect: Take 100μg of 30% acetic acid solution and drop it on a 1cm*2cm cotton pad, apply it to the inner arm area of ​​the subject, remove the cotton pad after 5 minutes, and immediately apply the same volume of protein solution, and use the area without any treatment as a blank control; take pictures at 0min, 1h and 6h after application. Figure 4 shown.

[0135] Depend on Figure 4 It can be seen from the test results shown that the recombinant mussel-like mucin provided by Examples 1 to 3 of the present invention has a good effect of protecting and accelerating the recovery of damaged skin stimulated by acetic acid solution, and has an excellent skin soothing effect.

[0136] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations on the present invention. A person skilled in the art may change, modify, replace and modify the above embodiments within the scope of the present invention without departing from the principles and intent of the present invention.

Claims

1. A recombinant mussel-like mucin, characterized in that: The recombinant mussel mucin comprises type III mussel mucin and a biologically functional peptide segment, wherein the type III mussel mucin and the biologically functional peptide segment are connected by a peptide bond; the biologically functional peptide segment comprises one or more of fragment I, fragment II and fragment III, wherein the amino acid sequence of fragment I is shown in SEQ ID NO:2, the amino acid sequence of fragment II is shown in SEQ ID NO:5, and the amino acid sequence of fragment III is shown in SEQ ID NO:

8.

2. The recombinant mussel-like mucin according to claim 1, wherein the amino acid sequence of the type III mussel mucin is shown in SEQ ID NO:

1.

3. The recombinant mussel-like mucin according to claim 1, characterized in that: The amino acid sequence of the recombinant mussel-like mucin is shown in SEQ ID NO: 3; Optionally, the amino acid sequence of the recombinant mussel-like mucin is as shown in SEQ ID NO: 6; Optionally, the amino acid sequence of the recombinant mussel-like mucin is as shown in SEQ ID NO:

9.

4. The recombinant mussel-like mucin according to claim 1, characterized in that: The DOPA content of the recombinant mussel-like mucin is 0.3-1.4 wt %.

5. A nucleic acid molecule, characterized in that The nucleic acid molecule encodes the recombinant mussel-like mucin according to any one of claims 1 to 4.

6. The nucleic acid molecule according to claim 5, characterized in that The nucleic acid molecule comprises one or more of the nucleotide fragments shown in SEQ ID NOs: 4, 7 and 10.

7. A fermentation strain, characterized in that: The fermentation strain synthesizes and expresses the recombinant mussel-like mucin according to any one of claims 1 to 4.

8. The method for preparing the recombinant mussel-like mucin according to any one of claims 1 to 4, characterized in that: The preparation method comprises: S1, introducing the nucleic acid molecule described in claim 5 or 6 into a host cell to obtain a fermentation strain; S2, fermenting and induced expression of the fermentation strain to obtain the recombinant mussel-like mucin; wherein DOPA and an inducing expression agent are added during the induced expression.

9. The method for preparing the recombinant mussel-like mucin according to claim 8, characterized in that: In step S2, the culture medium for fermentation culture is selected from one or more of LB culture medium, EMB culture medium, MAC culture medium and MS culture medium; Optionally, the cell inoculation amount of the fermentation culture is 0.5×10 5 ~1.5×10 5 / mL, temperature is 25-37℃, time is 4-8h; Optionally, in the induced expression, the concentration of DOPA is 0.1-1.0 g / L, and the concentration of the inducing expression agent is 0.1-1 mM; Optionally, the temperature for inducing expression is 16-37° C. and the time is 4-10 h.

10. Use of the recombinant mussel-like mucin according to any one of claims 1 to 4, the nucleic acid molecule according to claim 5 or 6 and / or the fermentation strain according to claim 7 in the field of medicine and / or cosmetics.

Citation Information

Patent Citations

  • Mussel attachment protein / amphoteric ion polypeptide fusion protein with attachment-anti-staining dual functions and synthesis method

    CN108503712A

  • Bionic recombinant III-type mussel mucin as well as preparation method and application thereof

    CN115819627A

  • Growth factor binding protein matrices

    CN116710477A

  • Recombinant mussel mucoprotein with natural activity as well as preparation method and application thereof

    CN117447611A

  • Method for altering hematopoietic progenitor cell adhesion, differentiation, and migration

    US20090130124A1

Cited By

  • Mussel mucoprotein synthesis method

    CN119751618A

  • Recombinant humanized 17-type collagen mussel mucin polypeptide as well as preparation method and application thereof

    CN119930841A

  • Recombinant human type 17 collagen mussel mucin polypeptide and its preparation method and use

    CN119930841B

  • Mussel byssus polypeptide with antibacterial property and application thereof

    CN120040572A

  • A mussel byssus polypeptide with antibacterial properties and its applications

    CN120040572B